Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; the references it cites are not checked yet.

Phase 3 Randomized Study of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplant (MAIA)

Abstract

Introduction Lenalidomide-based therapies are a standard of care for patients with newly diagnosed, transplant-ineligible MM. Daratumumab (DARA) is a human, CD38-targeted, IgG1κ monoclonal antibody which has single-agent activity in heavily pretreated MM patients. As previously reported in 3 phase 3 studies, the addition of DARA to standards of care in both relapsed refractory (D-Rd, DARA plus bortezomib and dexamethasone [D-Vd]) or transplant-ineligible NDMM (DARA plus bortezomib, melphalan, and prednisone [D-VMP]) resulted in a ≥50% reduction in the risk of disease progression or death (Palumbo A, et al. N Engl J Med 2016;375:754-766; Dimopoulos MA, et al. N Engl J Med 2016;375:1319-1331; Mateos MV, et al. N Engl J Med 2018;378:518-528). Of these, the POLLUX study with D-Rd showed the greatest benefit with a 63% reduction in risk of disease progression or death in patients with MM who had at least one prior line of therapy. Based on the efficacy and tolerable safety profile of D-Rd, we conducted a phase 3 study (MAIA) to evaluate D-Rd vs Rd in transplant-ineligible NDMM. Here we report the prespecified interim analysis of the MAIA study. Methods Patients ineligible for high-dose chemotherapy with autologous stem cell transplantation due to age ≥65 years or comorbidities were randomized 1:1 to Rd ± DARA. Stratification was based on International Staging System stage (ISS [I, II, III]), region (North America vs other), and age (<75 vs ≥75 years). All patients received 28-day…

Overview

Integrity signals

Registry

Crossref · 10.1182/blood-2018-120737

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

The citation lists are queued

They are fetched later and appear here then.

Cited by 50

Metadata

Authors
Facon, T., Kumar, S. K., Plesner, T., Orlowski, R. Z., Moreau, P., Bahlis, N., Basu, S., Nahi, H., Hulin, C., Quach, H., Goldschmidt, H., O'Dwyer, M., Perrot, A., Venner, C. P., Weisel, K., Mace, J. R., Ahmadi, T., Chiu, C., Wang, J., Van Rampelbergh, R., Uhlar, C. M., Kobos, R., Qi, M., & Usmani, S. Z.
Affiliations
  • Hôpital Claude Huriez (FR)
  • Mayo Clinic (US)
  • University of Southern Denmark (DK)
  • The University of Texas MD Anderson Cancer Center (US)
  • Nantes Université (FR)
  • University of Calgary (CA)
  • The Royal Wolverhampton NHS Trust (GB)
  • Karolinska University Hospital (SE)
  • Department of Hematology, Hospital Haut Leveque, University Hospital, Pessac, France
  • The University of Melbourne (AU)
  • University Hospital Heidelberg (DE)
  • Ollscoil na Gaillimhe – University of Galway (IE)
  • Centre Hospitalier Régional et Universitaire de Nancy (FR)
  • University of Alberta (CA)
  • Universitätsklinikum Tübingen (DE)
  • Florida Cancer Specialists & Research Institute (US)
  • Genmab (United States) (US)
  • Janssen Research & Development, LLC, Spring House, PA
  • Janssen Research & Development (United States) (US)
  • Janssen Research & Development, Beerse, Belgium
  • Levine Cancer Institute (US)
Corresponding author
  • Facon, Thierry
  • Orlowski, Robert Z.
  • Moreau, Philippe
  • Nahi, Hareth
  • Hulin, Cyrille
  • O'Dwyer, Michael
  • Perrot, Aurore
  • Weisel, Katja
  • Mace, Joseph R.
  • Ahmadi, Tahamtan
  • Wang, Jianping
  • Uhlar, Clarissa M.
Venue
Blood
Published
2018-11-29
Volume
132
Issue
Supplement 1
Pages
LBA-2-LBA-2
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W2901260218
Cited by
50
References
0
Citations by year
2025: 1 · 2024: 1 · 2022: 1 · 2021: 3 · 2020: 8 · 2019: 36
FWCI
8.43
Type
journal article
Language
en
Open access
closed
Locations
  • Blood (publishedVersion)
  • University of Southern Denmark Research Portal (University of Southern Denmark) (submittedVersion)
Topics
  • Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
  • Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
  • Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
Keywords
multiple myeloma, daratumumab, lenalidomide, dexamethasone, transplant-ineligible patients, newly diagnosed multiple myeloma, progression-free survival, overall survival, International Staging System, elderly patients, treatment safety, adverse events, immunogenicity, immunosuppression

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Phase 3 Randomized Study of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplant (MAIA). https://app.cochat.ai/papers/10.1182/blood-2018-120737
The paper
Facon, T., Kumar, S. K., Plesner, T., Orlowski, R. Z., Moreau, P., Bahlis, N., Basu, S., Nahi, H., Hulin, C., Quach, H., Goldschmidt, H., O'Dwyer, M., Perrot, A., Venner, C. P., Weisel, K., Mace, J. R., Ahmadi, T., Chiu, C., Wang, J., . . . Usmani, S. Z. (2018). Phase 3 Randomized Study of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplant (MAIA). Blood. https://doi.org/10.1182/blood-2018-120737

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.